# Hengrui Medicine
Latest news and articles about Hengrui Medicine
Total: 2 articles found
Hengrui’s Oral GLP‑1/GIP Candidate Shows Promising 26‑Week Weight Loss in China — A Potential Game‑Changer for Obesity Care
Hengrui Medicine and Kailera Therapeutics reported positive top‑line results from a 166‑participant Phase II trial of ripubopetide, an oral GLP‑1/GIP dual agonist, showing up to 12.1% mean weight loss at 26 weeks and manageable vomiting rates. Hengrui will pursue Phase III studies in China while Kailera plans a global Phase II in 2026, though larger, longer trials are needed to confirm efficacy and safety.
China Stocks See Narrow, Resource-Led Rally as Growth Names Slip; ChiNext Ends Lower
Chinese markets closed mixed as resource and commodity stocks powered a narrow rally while growth and health-care sectors lagged. Heavy turnover and a broad list of declining stocks indicate the advance was concentrated in a small number of themes, raising volatility and regulatory risks for investors.